Head-To-Head Contrast: Amarantus Bioscience (OTCMKTS:AMBS) & AMN Healthcare Services (NYSE:AMN)

AMN Healthcare Services (NYSE:AMN) and Amarantus Bioscience (OTCMKTS:AMBS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Earnings and Valuation

This table compares AMN Healthcare Services and Amarantus Bioscience”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73 billion	0.30	-$95.70 million	($2.49)	-8.43
Amarantus Bioscience	N/A	N/A	N/A	N/A	N/A

Amarantus Bioscience has lower revenue, but higher earnings than AMN Healthcare Services.

Profitability

This table compares AMN Healthcare Services and Amarantus Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-3.51%	8.05%	2.38%
Amarantus Bioscience	N/A	N/A	N/A

Risk & Volatility

AMN Healthcare Services has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Amarantus Bioscience has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AMN Healthcare Services and Amarantus Bioscience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2	2	4	1	2.44
Amarantus Bioscience	0	0	0	0	0.00

AMN Healthcare Services currently has a consensus target price of $22.64, indicating a potential upside of 7.83%. Given AMN Healthcare Services’ stronger consensus rating and higher probable upside, equities research analysts clearly believe AMN Healthcare Services is more favorable than Amarantus Bioscience.

Insider and Institutional Ownership

99.2% of AMN Healthcare Services shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by insiders. Comparatively, 10.3% of Amarantus Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

AMN Healthcare Services beats Amarantus Bioscience on 8 of the 11 factors compared between the two stocks.

About AMN Healthcare Services

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

About Amarantus Bioscience

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.